Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

NCT05322031 is registered in ClinicalTrials.gov with Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico as lead sponsor.

NCT NCT05322031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase
Phase 4
Overall status
Completed
Start date
August 1, 2022
Completion date
November 30, 2024
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognition disorder, myelin degeneration, schizophrenia